Full metadata record
DC FieldValueLanguage
dc.creatorTerpos, E. (Evangelos)-
dc.creatorKostopoulos, I.V. (Ioannis V.)-
dc.creatorKastritis, E. (Efstathios)-
dc.creatorNtanasis-Stathopoulos, I. (Ioannis)-
dc.creatorMigkou, M. (Magdalini)-
dc.creatorRousakis, P. (Pantelis)-
dc.creatorArgyriou, A.T. (Alexandra T.)-
dc.creatorKanellias, N. (Nikolaos)-
dc.creatorFotiou, D. (Despina)-
dc.creatorEleutherakis-Papaiakovou, E. (Evangelos)-
dc.creatorGavriatopoulou, M. (Maria)-
dc.creatorZiogas, D.C. (Dimitrios C.)-
dc.creatorPapanota, A.M. (Aristea-Maria)-
dc.creatorSpyropoulou-Vlachou, M. (Marilyn)-
dc.creatorTrougakos, I.P. (Ioannis P.)-
dc.creatorTsitsilonis, O.E. (Ourania E.)-
dc.creatorPaiva, B. (Bruno)-
dc.creatorDimopoulos, M.A. (Meletios A.)-
dc.date.accessioned2021-10-26T10:37:08Z-
dc.date.available2021-10-26T10:37:08Z-
dc.date.issued2019-
dc.identifier.citationTerpos, E. (Evangelos); Kostopoulos, I.V. (Ioannis V.); Kastritis, E. (Efstathios); et al. "Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy". HemaSphere. 3 (6), 2019, e300es
dc.identifier.issn2572-9241-
dc.identifier.urihttps://hdl.handle.net/10171/62276-
dc.description.abstractMinimal residual disease (MRD) was monitored in 52 patients with sustained CR (≥2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10−5; 17% at 10−6. All patients who relapsed during follow-up were MRD+ at the latest MRD assessment, including those with ultra-low tumor burden. MRD persistence was associated with specific phenotypic profiles: higher erythroblasts’ and tumor-associated monocytes/macrophages’ predominance in the bone marrow niche. NGF emerges as a suitable method for periodic, reproducible, highly-sensitive MRD-detection at the level of 10−6.es_ES
dc.language.isoenges_ES
dc.publisherOvid Technologies (Wolters Kluwer Health)es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectMinimal residual disease (MRD)es_ES
dc.subjectPhenotypic profileses_ES
dc.subjectSuitable methodes_ES
dc.subjectNext-generation flow (NGF)es_ES
dc.titleImpact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)es_ES
dc.identifier.doi10.1097/HS9.0000000000000300-
dadun.citation.number6es_ES
dadun.citation.publicationNameHemaSpherees_ES
dadun.citation.startingPagee300es_ES
dadun.citation.volume3es_ES

Files in This Item:
Thumbnail
File
Impact_of_Minimal_Residual_Disease_Detection_by.12.pdf
Description
Size
1.97 MB
Format
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.